Bladder cancer
Conditions
Interventions
Experimental Group:Oral adminstration of Miglitol
Sponsors
South China Hospital of Shenzhen University
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age 20-80 2) Pathological diagnosis of myometrial invasive bladder cancer (= T2) 3) The tumor invades the tissues around the bladder or adjacent organs (T3, T4) 4) Patients who require bladder preservation after full communication 5) Patients without indications for surgical treatment 6) After communication, they are willing to participate in the trial, promise to take medicine according to the doctor's instructions, and can follow up and communicate on time 7) No history of radiotherapy and chemotherapy, no history of other tumors
Exclusion criteria
Exclusion criteria: 1) Any of the following circumstances: people with immune deficiency or impairment (such as AIDS patients), who are using immunosuppressive drugs or radiotherapy; People suffering from fever and acute infectious diseases, including active tuberculosis, or those undergoing anti-tuberculosis treatment; Accompanied by severe chronic cardio-cerebrovascular disease or chronic kidney disease; 2) Those with other tumors; 3) Those who have received chemotherapy, radiotherapy and immunotherapy in the past 4 weeks (except for bladder infusion chemotherapy immediately after operation); 4) Bladder perforation is known or suspected during operation; 5) Patients with severe urethral stricture who cannot be placed cystoscope; 6) Pelvic CT or physical examination showed tumor metastasis; 7) Known to have low immune function, acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 8) Those suffering from serious cardio-cerebrovascular diseases, such as myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass surgery, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism, who cannot tolerate TURBT surgery; 9) There are obvious main visceral organ dysfunction, such as creatinine>1.5 times the upper limit of the normal value range, AST, ALT, total bilirubin>1.5 times the upper limit of the normal value range, etc; 10) Subjects with fever and body temperature exceeding 38 ? and obvious active infection that can affect the clinical trial, such as acute pneumonia, active tuberculosis and severe urinary tract infection; 11) Known opioid or alcohol addicts; 12) Those who have obvious gastrointestinal reactions after taking Miglitol; 13) Patients with inflammatory bowel disease, colon ulcer, incomplete intestinal obstruction, and tendency of intestinal obstruction; Chronic intestinal disease is accompanied by obvious gastrointestinal dysfunction, or with patients who may further aggravate the occurrence of flatulence; 14) Diabetes ketoacidosis poisoning; 15) Those who are allergic to the drug or its ingredients; 16) The investigator believes that there may be any situation that increases the risk of the subject or interferes with the execution of the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histopathological remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Image remission rate; | — |
Countries
China
Contacts
Public ContactLi Yuqing
South China Hospital of Shenzhen University
Outcome results
None listed